A phase ib-II study of dabrafenib, trametinib, cetuximab plus irinotecan in patients with BRAF mutant metastatic colorectal cancer: Subgroup analysis and biomarker identification
机构：[1]Sichuan Cancer Hospital and Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China四川省肿瘤医院
出处：
ISSN：
基金：
Chinese SouthWest Oncology Group [CSWOG202101002]; Health Commission of Sichuan Province [23LCYJ025]
第一作者机构：[1]Sichuan Cancer Hospital and Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China
推荐引用方式(GB/T 7714)：
Chen Yungchang,Hu Hai,Song Bo,et al.A phase ib-II study of dabrafenib, trametinib, cetuximab plus irinotecan in patients with BRAF mutant metastatic colorectal cancer: Subgroup analysis and biomarker identification[J].JOURNAL OF CLINICAL ONCOLOGY.2024,42(16):
APA：
Chen, Yungchang,Hu, Hai,Song, Bo,Shang, Jin,Man, Yuxin...&Lin, Tongyu.(2024).A phase ib-II study of dabrafenib, trametinib, cetuximab plus irinotecan in patients with BRAF mutant metastatic colorectal cancer: Subgroup analysis and biomarker identification.JOURNAL OF CLINICAL ONCOLOGY,42,(16)
MLA：
Chen, Yungchang,et al."A phase ib-II study of dabrafenib, trametinib, cetuximab plus irinotecan in patients with BRAF mutant metastatic colorectal cancer: Subgroup analysis and biomarker identification".JOURNAL OF CLINICAL ONCOLOGY 42..16(2024)
医学